Zoetis Expands Equine Diagnostics with Vetscan Enhancements as Q3 2026 Earnings Approaches

Zoetis Inc. is enhancing its point-of-care diagnostic offerings by introducing equine-specific hematology capabilities to its Vetscan OptiCell™ and Vetscan Imagyst® platforms, with global availability slated for October 2026. These updates extend the companies’ suite of rapid, AI-enabled diagnostics directly to equine veterinarians.

Announced in late September, the expansion allows Vetscan OptiCell to generate complete blood count (CBC) profiles customized for horses, while Vetscan Imagyst will support AI-powered blood smear analysis for equine samples. These enhancements are designed to streamline workflows and deliver faster, more reliable diagnostic insights in clinical settings. The updates are expected to roll out globally starting October 2026.

This development signals Zoetis’ continuing push into specialized veterinary diagnostics. By tailoring their platforms for equine medicine, the company is deepening its reach into new species and enhancing its Virtual Reference Laboratory capabilities, reflecting its strategic emphasis on cutting-edge, AI-integrated diagnostic tools.

Looking ahead, Zoetis is preparing for its third-quarter 2026 earnings results, with a webcast scheduled for November 5, 2026. Analysts and investors will be closely watching commentary on diagnostics, particularly updates on the integration of Vetscan innovations like these equine upgrades, as the company seeks to stabilize companion-animal demand and advance growth in diagnostics and livestock segments.

This equine diagnostics expansion is a clear indicator of Zoetis’ continued investment in precision veterinary care and underscores the importance of diagnostics in its broader growth strategy as it heads into the Q3 earnings report.

Verified source: Zoetis expands equine hematology capabilities, available globally from October 2026. This week’s announcement coincides with anticipation ahead of Zoetis’ Q3 webcast on November 5, 2026.